Literature DB >> 23350889

An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA.

Briseis Aschebrook-Kilfoy1, Donne Bennett D Caces, Nicholas J Ollberding, Sonali M Smith, Brian C-H Chiu.   

Abstract

Although an increased incidence of mantle cell lymphoma (MCL) has been reported, age-specific incidence patterns have not been described. Further analyses could inform investigation into the etiology of this disease. We conducted an epidemiologic study using the 13 Surveillance, Epidemiology, and End Results (SEER) registries to evaluate MCL incidence from 1992 through 2009. We calculated the proportional changes in the incidence of MCL for subpopulations defined by age, race/ethnicity and gender over time and the racial/ethnic and gender disparities. We observed a 130.9% increase in MCL incidence from 1992-1994 to 2005-2009. The increase was strongest for males (199.0%) and for whites (153.0%). The incidence increased 161%, 200%, 398% and 429% from 1992-1994 to 2005-2009 in white men ages 50-59, 60-69, 70-79 and 80+, respectively, whereas the increase in white females was 86%, 82%, 50% and 193% in the corresponding age groups. We observed a male-to-female incidence rate ratio (IRR) of 2.65 and a white-to-black IRR of 2.21. Our analysis confirmed significant increases in MCL, and illustrated that the incidence is increasing more rapidly in elderly persons, particularly in white males. We also identified novel age-specific temporal trends by race/ethnicity and sex. In addition, we found that the gender and white-to-black disparities have grown over time. Our findings may impact MCL etiologic investigation and treatment research.

Entities:  

Mesh:

Year:  2013        PMID: 23350889     DOI: 10.3109/10428194.2012.760041

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  14 in total

Review 1.  Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?

Authors:  Satish Shanbhag; Nina Wagner-Johnston; Richard F Ambinder; Richard J Jones
Journal:  Curr Oncol Rep       Date:  2019-06-10       Impact factor: 5.075

Review 2.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

3.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.

Authors:  Brian G Till; Hongli Li; Steven H Bernstein; Richard I Fisher; W Richard Burack; Lisa M Rimsza; Justin D Floyd; Marco A DaSilva; Dennis F Moore; Olga Pozdnyakova; Sonali M Smith; Michael LeBlanc; Jonathan W Friedberg
Journal:  Br J Haematol       Date:  2015-10-22       Impact factor: 6.998

4.  Immunohistochemical (IHC) Analysis of Non-Hodgkin's Lymphoma (NHL) Spectrum According to WHO/REAL Classification: A Single Centre Experience from Punjab, India.

Authors:  Manisha Sharma; Rahul Mannan; Mohit Madhukar; Sanjay Navani; Mridu Manjari; Tejinder Singh Bhasin; Karamjit Singh Gill
Journal:  J Clin Diagn Res       Date:  2013-01-12

5.  Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas.

Authors:  Shuangshuang Fu; Michael Wang; Ruosha Li; David R Lairson; Bo Zhao; Xianglin L Du
Journal:  Cancer Epidemiol       Date:  2018-12-06       Impact factor: 2.890

6.  Racial differences in mantle cell lymphoma in the United States.

Authors:  Yu Wang; Shuangge Ma
Journal:  BMC Cancer       Date:  2014-10-15       Impact factor: 4.638

7.  Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.

Authors:  Caixia Jing; Yuhuan Zheng; Yu Feng; Xia Cao; Caigang Xu
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

8.  Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.

Authors:  Byung Woog Kang; Sang Kyun Sohn; Joon Ho Moon; Yee Soo Chae; Jong Gwang Kim; Soo Jung Lee; Won Seog Kim; Je-Jung Lee; Se Ryeon Lee; Keon Uk Park; Ho Sup Lee; Won Sik Lee; Jong-Ho Won; Moo-Rim Park; Jae-Yong Kwak; Min Kyoung Kim; Hyo Jung Kim; Sung Yong Oh; Hye Jin Kang; Cheolwon Suh
Journal:  Blood Res       Date:  2014-03-24

9.  Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth.

Authors:  Fu-Lian Qu; Bing Xia; Su-Xia Li; Chen Tian; Hong-Liang Yang; Qian Li; Ya-Fei Wang; Yong Yu; Yi-Zhuo Zhang
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

10.  Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas.

Authors:  Shuangshuang Fu; Michael Wang; David R Lairson; Ruosha Li; Bo Zhao; Xianglin L Du
Journal:  Oncotarget       Date:  2017-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.